authors hypothesize that this trend could be attributable to cigarettes becoming more carcinogenic over time. Despite the trend toward lower "tar" and nicotine concentrations in cigarettes as measured by the Federal Trade Commission's testing protocol, the concentrations of specifi c carcinogens in cigarette smoke have increased. The concentrations of ␤ -naphthylamine increased 59% from 1968 to 1985 ( 8 ) . Between 1978 and 1995, measured concentrations of tobacco-specifi c nitrosamines in fi ltered cigarettes increased 17% for N ′ -nitrosonornicotine and 44% for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone ( 8 ) . Some cigarette additives may be direct carcinogens or procarcinogens that are activated following combustion ( 9 , 10 ) . Others may increase tobacco carcinogenicity indirectly by affecting metabolic activation; for example, menthol may increase membrane permeability, thereby increasing the likelihood of carcinogens interacting with DNA ( 11 ) .
The implementation of a consistent and methodologically rigorous case -control study protocol during an 11-year period in the same geographic region provides a unique opportunity to investigate whether risk estimates changed over this period. Even with these strengths, if the observed increase in the association of smoking with bladder cancer over time is genuine, it is remarkable that it could be detected in such a narrow time interval. To illustrate if we assume that the median age of the bladder cancer patients was 65 years ( 12 ) and that the average age of smoking initiation was 15 years, the midpoint calendar year of smoking initiation for each of the three successive calendar year groups studied would be 1946, 1950, and 1953 . If a substantial portion of each study group began smoking in these years and remained smokers thereafter, the study groups that are compared would have substantial overlap in the calendar years smoked, and hence comparable exposure to similar types of cigarettes across time. If changes in cigarette composition were the primary determinant of the stronger smoking and bladder cancer association observed in more recent years, an extremely potent increase in bladder carcinogenicity would be needed to result in detectable changes at the population level.
So far, the changing carcinogenic properties of cigarettes have been studied most extensively for lung cancer, and it is known that this risk has increased over time ( 13 ) . Furthermore, the relative risks of mortality from "other smoking-related cancers" increased for both men (RR = 2.7 to 3.5) and women (RR = 1.8 to 2.6) when a cohort established in 1959, with follow-up through 1965, and another cohort established in 1982, with follow-up through 1988, were compared ( 14 ) . In cohort studies carried out in the United States, that reported the RR for current smokers relative to nonsmokers in relation to bladder cancer incidence. No increase in the association was observed in successive and overlapping cohorts in Washington County, Maryland (RR = 2.7 for bladder cancer incidence in current smokers relative to nonsmokers in the fi rst cohort, followed from 1963 to 1988; RR = 2.6 in the second cohort, followed from 1975 to 1994) (15) . A similar relative risk (RR = 2.9) was reported in a Hawaiian cohort followed from 1966 to 1988 ( 16 ) . In a few recent cohort studies, reported RRs of bladder cancer incidence among current smokers relative to nonsmokers were notably higher: 5.7 in Seventh Day Adventists followed from 1976 to 1982 ( 17 ) and 5.5 in the Iowa Women's Health Study cohort followed from 1986 to 1998 ( 18 ) . This evidence is equivocal but certainly does not rule out that the association has grown stronger over time.
The fi ndings of Baris et al. (7) are provocative and are accompanied by a tenable hypothesis. Recalling the steady accumulation of evidence and the cautious inferences that eventually led to the determination that smoking causes bladder cancer, these intriguing fi ndings offer a testable hypothesis that warrants thorough investigation. An important element of this research will be to more precisely, pinpoint the specifi c role of cigarette additives will be an important element of this research. This study highlights the need for continued vigilance in monitoring the impact of changing cigarette content and design on disease risk, and demonstrates that the public health implications of the changing cigarette content and design are potentially severe.
